Litcius/Paper detail

Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma

Seon-Hyeong Lee, Joon Hee Kang, Ji Sun Ha, Jae‐Seon Lee, Soo Jin Oh, Hyun-Jung Choi, Jaewhan Song, Soo‐Youl Kim

2020International Journal of Molecular Sciences29 citationsDOIOpen Access PDF

Abstract

Angiogenesis and the expression of vascular endothelial growth factor (VEGF) are increased in renal cell carcinoma (RCC). Transglutaminase 2 (TGase 2), which promotes angiogenesis in endothelial cells during wound healing, is upregulated in RCC. Tumor angiogenesis involves three domains: cancer cells, the extracellular matrix, and endothelial cells. TGase 2 stabilizes VEGF in the extracellular matrix and promotes VEGFR-2 nuclear translocation in endothelial cells. However, the role of TGase 2 in angiogenesis in the cancer cell domain remains unclear. Hypoxia-inducible factor (HIF)-1α-mediated VEGF production underlies the induction of angiogenesis in cancer cells. In this study, we show that p53 downregulated HIF-1α in RCC, and p53 overexpression decreased VEGF production. Increased TGase 2 promoted angiogenesis by inducing p53 degradation, leading to the activation of HIF-1α. The interaction of HIF-1α and p53 with the cofactor p300 is required for stable transcriptional activation. We found that TGase 2-mediated p53 depletion increased the availability of p300 for HIF-1α-p300 binding. A preclinical xenograft model suggested that TGase 2 inhibition can reverse angiogenesis in RCC.

Topics & Concepts

AngiogenesisCancer researchVascular endothelial growth factorHypoxia-inducible factorsExtracellular matrixVascular endothelial growth factor AEndothelial stem cellDownregulation and upregulationHIF1AChemistryCancer cellAngiogenesis inhibitorBiologyCell biologyCancerBiochemistryVEGF receptorsIn vitroGeneGeneticsBlood properties and coagulationLipid metabolism and disordersErythrocyte Function and Pathophysiology